GEN İlaç
GEN is the leading specialty pharmaceutical company in Turkey with more than 20 years of experience. GEN partners with global pharmaceutical companies to bring innovative therapies and rare solutions to the community. GEN works compliant with ethical and scientific principles and strives to set the best standards for quality, safety, and value in the manufacture and access to health care products. With its GMP certificated production facility and R&D center based in Ankara, GEN offers solutions around the globe in the treatment of rare diseases and disorders. In addition to its HQ and offices in Turkey, GEN has offices in Germany, Russia, Kazakhstan, Uzbekistan, and Azerbaijan.
OneLife (İstanbul Portföy Yönetimi)
Established in 2007, Istanbul Portföy Yönetimi Asset Management is Turkey’s largest domestic and independent portfolio management company with a fund size of 16.7 billion TL as of November 2021. It has included the healthcare industry in its focus areas by adding “One Life Ventures” Venture Capital Investment Fund to the 10 venture capital investment funds in its portfolio in August 2021.
Eczacıbaşı Momentum
Established in 2019 as a corporate venture capital fund of Eczacıbaşı Holding, Eczacıbaşı Momentum aims to invest high-impact start-ups and technologies. The purpose of the fund is to invest in start-ups that are active in wellbeing, consumption, and home-living, that shape the new normal of modern life, and that have an international perspective. Eczacıbaşı Momentum’s focus, in this context, is new technologies and business models. In addition to gain financial returns, start-ups also benefit from the knowledge and business relations of the Eczacıbaşı Group. To date, Eczacıbaşı Momentum has made twelve investments both from Turkey and abroad.
ACT Venture Partners
ACT Venture Partners was founded in July 2015 as a venture capital firm that invests in early stage technology and innovation opportunities in Turkey. The anchor investor is the European Investment Fund (EIF) along with a number of private and institutional investors in the group.
